12:00 AM
Mar 05, 2012
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Amicus Therapeutics preclinical data

AT3375 as monotherapy increased glucocerebrosidase (GBA; GCase) activity in Gaucher's disease patient-derived cells with greater potency compared to AT2101. AT3375 is a next-generation version of the company's AT2101,...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >